A Phase 3 interventional study of Keppra XR (Levetiracetam XR) in Epilepsy, sponsored by UCB Pharma. Completed at 37 sites in 4 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-09-05.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.
Among the 60 studies testing levetiracetam in Epilepsy, this one is the 19th largest by enrollment, is one of 7 that started in 2007, is one of 28 in phase 3, and was the 19th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 40+
Waad Alkathiri · Sites in Saudi Arabia
Ages 18+
Xiangya Hospital of Central South University · Sites in China
Ages 18–80
National Taiwan University Hospital
Ages 20+
By country, each count listing its studies:
Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 28 · Phase 4 13
First in 1998; this study’s year is marked. 7 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 190 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 60 interventional studies. Of the 55 that completed or were terminated, 31 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 47th largest by enrollment of the 116 interventional ones that give a count, is one of 9 that started in 2007, is one of 74 in phase 3, and was the 28th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 60 studies testing levetiracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To provide continued treatment of Keppra XR (Levetiracetam XR) and to assess the long term safety of Keppra XR in subjects with partial onset seizures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1000 - 3000 mg/day Keppra XR (Levetiracetam XR), flexible dosing, throughout the duration of the study (planned: approximately 6 months-3 years)
Drug: Keppra XR (Levetiracetam XR)
500 mg tablets, 1000 - 3000 mg/day, flexible dosing for duration of the study (planned: approximately 6 months-3 years).
Also known as: Keppra XR
Number of Subjects Who Experienced at Least 1 Treatment Emergent Adverse Event During the Actual Treatment Period (6 Months-2 Years)
An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Duration of the Treatment Period (6 months-2 years)
Number of Subjects Who Experienced at Least 1 Serious Treatment Emergent Adverse Event During the Actual Treatment Period (6 Months-2 Years)
A serious adverse event is any untoward medical occurrences in a subject administered study treatment, whether or not the event is related to treatment, with at least one of the follow outcomes: death, life-threatening, initial inpatient hospitalization or prolongation of hospitalization, significant or persistent disability/incapacity, congenital anomaly/birth defect, or an important medical event that may jeopardize the subject and require a medical/surgical intervention.
Time frame: Duration of the Treatment Period (6 months-2 years)
Number of Subjects Prematurely Discontinuing Due to a Treatment-emergent Adverse Event During the Actual Treatment Period
An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Duration of the Treatment Period (6 months-2 years)
Percentage of Subjects Remaining on Keppra XR Monotherapy From Study Entry Through 6 Months
Among subjects in the Efficacy (EFF) population entering the study on Keppra XR monotherapy and exposed for at least 6 months, is the percentage of subjects remaining on monotherapy treatment for at least 6 months.
Time frame: Study entry through 6 months
Percentage of Subjects Remaining on Keppra XR Monotherapy From Study Entry Through 12 Months
Among subjects in the Efficacy (EFF) population entering the study on Keppra XR monotherapy and exposed for at least 6 months, is the percentage of subjects remaining on monotherapy treatment for at least 12 months.
Time frame: Study entry through 12 months
The study began December 2007 recruiting in the United States, Poland, Mexico, and the Russian Federation. The study completed March 2010.
| Milestone | Keppra XR (Levetiracetam XR) |
|---|---|
| Started | 190 |
| Completed | 166 |
| Not completed | 24 |
| Withdrew: Adverse event | 5 |
| Withdrew: Protocol violation | 5 |
| Withdrew: Withdrawal by subject | 7 |
| Withdrew: Other: sponsor request | 3 |
| Withdrew: Other: subject had temporal lobectomy | 1 |
| Withdrew: Other: site closure | 1 |
| Withdrew: Other: other health problems | 1 |
| Withdrew: Other: investigator decision | 1 |
An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
| number of subjects | Keppra XR |
|---|---|
| Number of Subjects Who Experienced at Least 1 Treatment Emergent Adverse Event During the Actual Treatment Period (6 Months-2 Years) | 126 |
A serious adverse event is any untoward medical occurrences in a subject administered study treatment, whether or not the event is related to treatment, with at least one of the follow outcomes: death, life-threatening, initial inpatient hospitalization or prolongation of hospitalization, significant or persistent disability/incapacity, congenital anomaly/birth defect, or an important medical event that may jeopardize the subject and require a medical/surgical intervention.
| number of subjects | Keppra XR |
|---|---|
| Number of Subjects Who Experienced at Least 1 Serious Treatment Emergent Adverse Event During the Actual Treatment Period (6 Months-2 Years) | 22 |
An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
| number of subjects | Keppra XR |
|---|---|
| Number of Subjects Prematurely Discontinuing Due to a Treatment-emergent Adverse Event During the Actual Treatment Period | 5 |
Among subjects in the Efficacy (EFF) population entering the study on Keppra XR monotherapy and exposed for at least 6 months, is the percentage of subjects remaining on monotherapy treatment for at least 6 months.
| percentage of subjects | Keppra XR |
|---|---|
| Percentage of Subjects Remaining on Keppra XR Monotherapy From Study Entry Through 6 Months | 77.0 |
Among subjects in the Efficacy (EFF) population entering the study on Keppra XR monotherapy and exposed for at least 6 months, is the percentage of subjects remaining on monotherapy treatment for at least 12 months.
| percentage of subjects | Keppra XR |
|---|---|
| Percentage of Subjects Remaining on Keppra XR Monotherapy From Study Entry Through 12 Months | 65.3 |
Collected over Up to two years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Keppra XR (Levetiracetam XR) | — | 22/189 (11.6%) | 57/189 (30.2%) |
| Event | Keppra XR (Levetiracetam XR) |
|---|---|
| ConvulsionNervous system disorders | 4/189 |
| Chest painGeneral disorders | 2/189 |
| Angina pectorisCardiac disorders | 1/189 |
| Abdominal painGastrointestinal disorders | 1/189 |
| DrowningGeneral disorders | 1/189 |
| Non-cardiac chest painGeneral disorders | 1/189 |
| Bile duct stoneHepatobiliary disorders | 1/189 |
| CholangitisHepatobiliary disorders | 1/189 |
| CholecystitisHepatobiliary disorders | 1/189 |
| Hepatic cirrhosisHepatobiliary disorders | 1/189 |
| Event | Keppra XR (Levetiracetam XR) |
|---|---|
| HeadacheNervous system disorders | 26/189 |
| NasopharyngitisInfections and infestations | 15/189 |
| SomnolenceNervous system disorders | 15/189 |
| InfluenzaInfections and infestations | 14/189 |
| DizzinessNervous system disorders | 10/189 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/189 |
| Age, Categorical(Participants) | Keppra XR (Levetiracetam XR) |
|---|---|
| <=18 years | 40 |
| Between 18 and 65 years | 147 |
| >=65 years | 3 |
| Age, Continuous(years) | Keppra XR (Levetiracetam XR) |
|---|---|
| Mean | 33.44 ± 14.46 |
| Sex: Female, Male(Participants) | Keppra XR (Levetiracetam XR) |
|---|---|
| Female | 111 |
| Male | 79 |
| Region of Enrollment(participants) | Keppra XR (Levetiracetam XR) |
|---|---|
| United States | 26 |
| Mexico | 49 |
| Poland | 59 |
| Russian Federation | 56 |
The record gives a start of Dec 2007, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam